| Literature DB >> 30200664 |
Caterina R de Vera1,2, Guillermo Díaz Crespín3,4, Antonio Hernández Daranas5,6, Sofia Montalvão Looga7, Katja-Emilia Lillsunde8, Päivi Tammela9, Merja Perälä10, Vesa Hongisto11, Johannes Virtanen12, Heiko Rischer13, Christian D Muller14, Manuel Norte15,16, José J Fernández17,18, María L Souto19,20.
Abstract
The study of marine natural products for their bioactive potential has gained strength in recent years. Oceans harbor a vast variety of organisms that offer a biological and chemical diversity with metabolic abilities unrivalled in terrestrial systems, which makes them an attractive target for bioprospecting as an almost untapped resource of biotechnological applications. Among them, there is no doubt that microalgae could become genuine "cell factories" for the biological synthesis of bioactive substances. Thus, in the course of inter-laboratory collaboration sponsored by the European Union (7th FP) into the MAREX Project focused on the discovery of novel bioactive compounds of marine origin for the European industry, a bioprospecting study on 33 microalgae strains was carried out. The strains were cultured at laboratory scale. Two extracts were prepared for each one (biomass and cell free culture medium) and, thus, screened to provide information on the antimicrobial, the anti-proliferative, and the apoptotic potential of the studied extracts. The outcome of this study provides additional scientific data for the selection of Alexadrium tamarensis WE, Gambierdiscus australes, Prorocentrum arenarium, Prorocentrum hoffmannianum, and Prorocentrum reticulatum (Pr-3) for further investigation and offers support for the continued research of new potential drugs for human therapeutics from cultured microalgae.Entities:
Keywords: bioactive compound; bioprospecting; blue biotechnology; drug discovery; marine microalgae; marine natural products
Mesh:
Substances:
Year: 2018 PMID: 30200664 PMCID: PMC6164378 DOI: 10.3390/md16090317
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Antimicrobial screening results for microalgae extracts (biomass extracts: dark bars, cell free culture medium extracts: light bars) at 100 µg/mL concentration against: (A) E. faecalis (ATCC 29212), (B) S. aureus (ATCC 25923), (C) E. coli (ATCC 25922), and (D) C. albicans (ATCC 90028). Ciprofloxacin was used as a reference antibiotic in the antibacterial assays. MIC90 (minimum inhibitory concentration) values for E. faecalis, S. aureus, and E. coli were 3, 1.5, and 0.048 μM (1, 0.5 and 0.016 μg/mL), respectively. Amphotericin B was used as a reference in the antifungal assay (MIC90 = 0.5 μM (0.5 μg/mL)).
Figure 2Inhibition of CHIKV replicon (%) of microalgae extracts at 100 µg/mL. Dark bars represent biomass extracts and light bar cell free culture medium extracts.
Figure 3Growth inhibition (%) against cell lines: MCF-10A (breast cells), MCF-7 (breast cancer cells), LNCaP, and PC-3 (prostate cancer cells). All the samples were tested at 50 µg/mL.
Figure 4Dose-response results for anti-proliferative activity for selected specimen against tumorigenic (MCF-7) and non-tumorigenic (MCF-10A) breast cell lines and two tumorigenic prostate cell lines (LNCaP, PC-3) at 0.5 µg/mL (green), 5 µg/mL (purple), and 50 µg/mL (blue) concentration.
Figure 5Apoptosis inducing activities (%) of HEPG-2 hepatocytes. Dark bars represent biomass extracts and light bar cell free culture medium extracts. Test carried out at 100 µg/mL.
Figure 6Distribution of the microalgae strains evaluated in this study as a function of their phylum including a proportion of active or inactive extracts in each case.